Save the Date!

Cholangiocarcinoma Foundation Annual Conference
February 4-5, 2016
Salt Lake City, Utah

In cooperation with:

Oral Abstracts and Poster Sessions

The Cholangiocarcinoma Foundation Annual Conference Poster Session will provide an opportunity for presenting late-breaking results, on-going research projects, and speculative or innovative work in cholangiocarcinoma research. Posters are intended to provide authors and conference participants with the ability to connect with each other and build upon the foundation of knowledge exchange and collaboration.

Oral Abstract Presentations

Dr. Renuka Iyer, Roswell Park Cancer Institute
Gemcitabine, Capecitabine & Bevacizumab in Patients with Advanced BC- Final Results of a Multicenter Phase II Study

Dr. Supriya Saha, Massachusetts General Hospital Cancer Center
Using Model Systems to Understand IDH Mutant Cholangiocarcinoma

Rachna Shroff, The University of Texas MD Anderson Cancer Center
Retrospective Review of Treatment Given to Unresectable Cholangiocarcinoma Patients: What is the Role of Chemoradiation?

Dr. Daniela Sia, Icahn School of Medicine at Mount Sinai
Massive Parallel Sequencing Uncovers Actionable FGFR2-PPHLN1 Fusion and ARAF Mutations in Intrahepatic Cholangiocarcinoma

Huiping Zhou, Virginia Commonwealth University
Conjugated Bile Acids Promote Cholangiocarcinoma Cell Invasive Growth via Activation of Sphingosine 1-phosphate Receptor 2

Poster Presentations

Roongruedee Chaiteerakij, Mayo Clinic
Difference in pattern of somatic mutations between PSC-related CCA and non-PSC related CCA

Jack Chen and Jiarui Li, Simon Fraser University
Mutational Landscape of Intrahepatic Cholangiocarcinoma

Nasra Giama, Mayo Clinic
The International Hepatobiliary Neoplasia Registry and Biorepository

Talia Golan, Sheba Medical Clinic, Israel
Biliary and Pancreatic Malignancies in Jewish BRCA1 and BRCA2 Mutation Carriers

Lipika Goyal, MGH Cancer Center
A Phase II trial of Cabozantinib (XL-184) in Patients with Advanced Cholangiocarcinoma (CCA)

Isabella Guajardo, UCSF
Cholangiocarcinoma and the Internet: What Doctors Need to Know to Best Help Your Patients

Margaret Hill, University of Rochester
Mcl-1 Regulates Autophagy in Intrahepatic Cholangiocarcinoma

Muthusamy Kunnimalaiyaan, Medical College of Wisconsin
Targeted Inhibition of the Akt Pathway in Cholangiocarcinoma by MK2206

Yong Sun Lee, University of Texas Medical Branch
nc886, a Cellular Non-Coding RNA that Plays a Tumor Surveillance Role in the Protein Kinase R Pathway in Cholangiocarcinoma

Maria Lozada, Medical Clinic
A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma

Lauren Rosati, Johns Hopkins University
Adjuvant Chemoradiation Therapy in Cholangiocarcinoma: A Single-Institution Experience

Hassan Shaleh, Mayo Clinic
Antitumor Effect of the Potent FGFR Inhibitor Ponatinib on an FGFR2-Fusion Driven Cholangiocarcinoma Mouse Model

Rachna Shroff, The University of Texas MD Anderson Cancer Center
Orthotopic liver transplant (OLT) in the Treatment of Hilar and Intrahepatic Cholangiocarcinomas: Preliminary Experience

Yaman Suleiman, H. Lee Moffitt Cancer Center and Research Institute
The Influence and Prognostic Value of Tumor-Infiltrating Lymphocytes (TILs) and PD-L1 Overexpression in Cholangiocarcinoma

Suebpong Tanasanvimon, Chulalongkorn University, Thailand
A Comparison of miRNA Expression Patterns between OV-CCA and non-OV CCA

Mingxin Zuo, UT MD Anderson Cancer Center
Novel Therapeutic Strategy Targeting Hedgehog Signaling & mTOR Pathways in Biliary Cancer